Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine Journal Article


Authors: Yarchoan, R.; Brouwers, P.; Spitzer, A. R.; Grafman, J.; Safai, B.; Perno, C. F.; Larson, S. M.; Berg, G.; Fischl, M. A.; Wichman, A.; Thomas, R. V.; Brunetti, A.; Schmidt, P. J.; Myers, C. E.; Broder, S.
Article Title: Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine
Abstract: Four patients with human-immunodeficiency-virus-associated neurological disease were treated with 3'-azido-3'-deoxythymidine (AZT). Three (two with chronic dementia, and one with chronic dementia and peripheral neuropathy) improved as assessed by clinical examination, psychometric tests, nerve conduction studies, and/or positron emission tomography; there was no improvement in the fourth patient who presented with paraplegia. These results support the hypothesis that certain AIDS-virus-associated neurological abnormalities are reversible by antiretroviral chemotherapy. © 1987.
Keywords: adult; middle aged; case report; drug efficacy; peripheral neuropathy; central nervous system; diagnosis; dementia; brain disease; brain diseases; drug derivative; antivirus agent; acquired immune deficiency syndrome; acquired immunodeficiency syndrome; drug therapy; neurologic disease; therapy; thymidine; peripheral nervous system; human immunodeficiency virus 1; zidovudine; nervous system; nervous system diseases; paraplegia; humans; human; male; priority journal; article; analogs and derivatives
Journal Title: Lancet
Volume: 329
Issue: 8525
ISSN: 0140-6736
Publisher: Elsevier Science, Inc.  
Date Published: 1987-01-17
Start Page: 132
End Page: 135
Language: English
DOI: 10.1016/s0140-6736(87)91968-4
PUBMED: 2879972
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Bijan Safai
    52 Safai